You might also like
Clinical Case Study Compendium:
Video case report 5
Real-World Experiences by prof. dr. M. Beckers, UZ Leuven. Video of case report 5
View more
Part 1: Clinical Case Study Compendium:
PDF case reports 1 & 2
The impact of gilteritinib in daily practice as salvage treatment and as bridging therapy. Real-World
View more
Gilteritinib as salvage- and MRD-directed therapy in an early post-allo FLT3-ITD AML¹ relapse
In this interview, Prof. Dr. M. Beckers (University Hospital Leuven; Belgium) talks about her experiences with gilteritinib after an early post-allo FLT3-ITD AML1 relapse, which ultimately led to molecular complete remission.
Intended for: practitioners hematology
Why: up-to-date knowledge TKI2 related target therapy
When: read now
1: FMS-like Tyrosine Kinase 3-ITD mutated Acute Myeloid Leukemia; 2: Tyrosine Kinase Inhibitor.
MAT-BE-XOS-2026-00011 APR 2026
AML: Acute Myeloid Leukemia
COPYRIGHT © 2026 ASTELLAS PHARMA B.V. MAT-BE-XOS-2025-00030 - DEC 2025